M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients With Hemorrhagic Cystitis

Not Applicable

Withdrawn

Conditions: Bladder Diseases
Cystitis

Interventions: Drug: Cidofovir

First Posted Date: 2009-08-11

Last Posted Date: 2019-05-14

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00956176

STAT3 Inhibitor for Solid Tumors

Phase 1

Completed

Conditions: Advanced Cancer
Solid Tumor

Interventions: Drug: OPB-31121

First Posted Date: 2009-08-10

Last Posted Date: 2013-02-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00955812

Locations: 🇺🇸
Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase Ib Study of Erlotinib Prior to Surgery in Patients with Head and Neck Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Head and Neck Carcinoma
Recurrent Salivary Gland Carcinoma
Recurrent Skin Carcinoma
Skin Squamous Cell Carcinoma

Interventions: Drug: Erlotinib Hydrochloride
Other: Laboratory Biomarker Analysis

First Posted Date: 2009-08-07

Last Posted Date: 2024-10-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT00954226

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Phase 2

Completed

Conditions: Hematologic Diseases
Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Chronic Myelogenous Leukemia

Interventions: Drug: Ondansetron
Drug: Aprepitant

First Posted Date: 2009-08-07

Last Posted Date: 2015-06-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT00954941

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema

Not Applicable

Withdrawn

Conditions: Lymphedema
Oropharyngeal Cancer
Head and Neck Cancer
Oral Cancer

Interventions: Other: Follow -Up Visits
Other: Modified CDT Program
Other: Full CDT

First Posted Date: 2009-08-04

Last Posted Date: 2012-09-07

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00951470

Stereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases

Phase 3

Active, not recruiting

Conditions: Metastatic Malignant Neoplasm in the Brain

Interventions: Radiation: Stereotactic Radiosurgery

First Posted Date: 2009-07-31

Last Posted Date: 2024-08-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 132

Registration Number: NCT00950001

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials

Completed

Conditions: Advanced Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2009-07-30

Last Posted Date: 2016-04-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 309

Registration Number: NCT00949390

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Mobile Smoking Cessation Intervention in Enhancing Cancer Outreach in Low-Income Adult Smokers

Not Applicable

Completed

Conditions: Cigarette Smoker
Current Every Day Smoker

Interventions: Other: Laboratory Biomarker Analysis
Behavioral: Smoking Cessation Intervention
Other: Tobacco Cessation Counseling
Behavioral: Telephone-Based Intervention

First Posted Date: 2009-07-29

Last Posted Date: 2023-01-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 626

Registration Number: NCT00948129

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Vorinostat
Drug: Azacitidine

First Posted Date: 2009-07-29

Last Posted Date: 2020-02-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 110

Registration Number: NCT00948064

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Project COMBAT: Combating Tobacco Use in the United States Army

Withdrawn

Conditions: Smoking
Smoking Cessation

Interventions: Behavioral: Video Game
Behavioral: Pamphlet
Behavioral: Surveys

First Posted Date: 2009-07-29

Last Posted Date: 2016-07-21

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00948233

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy